[vc_row top_margin=”none” el_position=”first”] [vc_column top_margin=”none”] [mc_carousel id=”carousel” carousel_images=”2773,2772,2771,2770″ features_images_loop=”1″ lightbox_icon_color=”blue_light” autoplay=”0″ pause_on_hover=”1″ scroll=”1″ effect=”scroll” easing=”swing” duration=”500″ top_margin=”page_margin_top_section” el_position=”first last”] [/vc_column] [/vc_row] [vc_row top_margin=”none” el_position=”last”] [vc_column top_margin=”none”] [vc_column_text el_position=”first last”]
CRISPR-Based System Identifies Important New Drug Targets in a Deadly Leukemia-Cold Spring Harbor Laboratory
March 8, 2018
https://medicalxpress.com/news/2018-03-crispr-based-important-drug-deadly-leukemia.html
New Therapies for Acute Leukemia
March, 2018
http://www.onclive.com/web-exclusives/expert-highlights-gamechanging-therapies-for-acute-leukemia
New Drug target for leukemia identified
Medical News Today
July 31, 2014
http://www.medicalnewstoday.com/articles/280440.phpLiver Cancer
European Commission Approves Roche Leukemia Treatment
The Wall Street Journal
July 29, 2014
http://online.wsj.com/articles/european-commission-approves-roche-leukemia-treatment-1406614865
FDA expands approved use of Imbruvica for chronic lymphocytic leukemia
FDA News Release
July 28, 2014
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406916.htm
FDA approves idelalisib for three leukemia and lymphoma indications
The Oncology Report
July 23, 2014
http://www.oncologypractice.com/oncologyreport/home/article/fda-approves-idelalisib-for-three-leukemia-and-lymphoma-indications/1e0c726a08e9781744ddd696e94b58ce.html
Novartis Wins ‘Breakthrough’ Status for New Leukemia treatment
The Wall Street Journal
July 7, 2014
http://online.wsj.com/articles/novartis-wins-breakthrough-status-for-new-leukemia-treatment-1404758105
Now Enrolling Patients for AML and CLL Clinical Trials at Manhattan Hematology Oncology Associates.
[/vc_column_text] [/vc_column] [/vc_row]